Latest Breaking News On - Yuhan corporation of korea - Page 1 : comparemela.com

Sorrento Announces Positive Phase II Results of PD-L1

IMC-001, a PD-L1 monoclonal antibody selected from Sorrento’s G-MAB library, demonstrated impressive therapeutic effects in patients with heavily treated.

South koreaSeog kimBrian cooleyHenry jiImmuneoncia seongnamSemnur pharmaceuticals incAsian congressExchange commissionSorrento therapeutics incSamsung medical centerImmuneoncia therapeuticsPivotal trialc le ar programScilex pharmaceuticals incEuropean society for medical oncologyYuhan corporation of koreaYuhan corporation

Sorrento Therapeutics (SRNE) Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology

Sorrento Therapeutics (SRNE) Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South koreaSeog kimHenry jiImmuneoncia seongnamSorrento therapeutics incSamsung medical centerImmuneoncia therapeuticsAsian congressYuhan corporation of koreaEuropean society for medical oncologyYuhan corporationEuropean societyMedical oncologyWon seog kimPrincipal investigatorTae kim